Clinical Trials

I CAN is a Phase 3, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of ravulizumab (ALXN1210) in adults with immunoglobulin A nephropathy (IgAN).

Have you been diagnosed with IgA nephropathy? The ASSIST study is a phase 2, randomized, placebo-controlled, cross-over study of atrasentan* in adults with IgA nephropathy (IgAN). The ASSIST study is a clinical trial that will test an investigational drug named atrasentan, which is being developed for the treatment of IgAN, …

Are you living with IgA nephropathy? The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study of zigakibart(BION-1301) in adults with IgA nephropathy (IgAN). The BEYOND study is a clinical trial that willtest an investigational drug named zigakibart which is being developed for the treatment ofIgAN. The goal of …

Travere Therapeutics is evaluating a study medication called sparsentan to determine if it will be a safe and effective treatment that helps slow the decline of kidney function in children living with rare kidney diseases.

 IMAGINATION is a phase 3, randomized, double-blind, placebo-controlled trial that aims to evaluate a novel therapy, Sefaxersen (RO7434656), in adults with IgA nephropathy to establish its effectiveness and safety in treating this condition.

Efficacy and safety of extended TARPEYO® (budesonide) delayed release capsules treatment beyond 9 months in adult patients The study assesses the efficacy and safety of extended TARPEYO® treatment in adult participants who have completed 9 months of TARPEYO 16 mg daily treatment. The study treatment period is 15 months; TARPEYO 16 mg daily dose will be taken for 6-months followed by 8 mg daily dose for 9-months.

ORIGIN 3 is a Phase 3 clinical trial researching an investigational medication called atacicept in adults with IgAN. The trial will measure the effectiveness of atacicept at improving kidney function by preventing damage caused by the buildup of IgA in the kidneys.

A Phase 2 Study to Evaluate the Safety, Pharmacology, Pharmacokinetics, and Clinical Activity of ADX-097 in Adult Patients with Primary IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy

The RAINIER Study: RAINIER is a phase 3 registrational, randomized, placebo-controlled study of povetacicept in adults with IgA Nephropathy (IgAN). The drug is administered once every 4 weeks as a subcutaneous injection. There is a 2 in 3 (67%) chance of receiving study drug and a 1 and 3 (33%) chance of receiving placebo (an inactive substance

VISIONARY: A Phase 3 clinical trial of sibeprenlimab for adults with IgA Nephropathy. Targeting a brighter future for IgAN patients.